CG Oncology, Inc. (CGON)
72.59
-0.05
(-0.07%)
USD |
NASDAQ |
Nov 11, 16:00
72.59
0.00 (0.00%)
After-Hours: 19:18
CG Oncology Net Income (Quarterly) : -56.89M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -56.89M |
| June 30, 2026 | -79.06M |
| March 31, 2026 | -60.20M |
| December 31, 2025 | -41.31M |
| September 30, 2025 | -43.81M |
| June 30, 2025 | -41.43M |
| March 31, 2025 | -34.45M |
| December 31, 2024 | -31.80M |
| Date | Value |
|---|---|
| September 30, 2024 | -20.40M |
| June 30, 2024 | -18.90M |
| March 31, 2024 | -16.93M |
| December 31, 2023 | -16.12M |
| September 30, 2023 | -12.21M |
| June 30, 2023 | -11.61M |
| March 31, 2023 | -8.667M |
| December 31, 2022 | -8.392M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -28.46M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.604M |
| Total Expenses (Quarterly) | 58.50M |
| EPS Diluted (Quarterly) | -0.6402 |
| Enterprise Value | 5.512B |
| Gross Profit Margin (Quarterly) | -66.40% |
| Profit Margin (Quarterly) | -3.55K% |
| Earnings Yield | -3.81% |
| Normalized Earnings Yield | -3.808 |